Introduction: A New Tool for Breast Cancer Treatment On September 25, 2025, the FDA approved Inluriyo (imlunestrant), an oral selective estrogen receptor degrader (SERD), for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer (MBC) after progression on endocrine therapy (ET). 0 For oncologists, this Inluriyo FDA approval offers a targeted oral therapy to tackle ET … Continue reading FDA Approves Inluriyo / Imlunestran: Oncology Guidance for ESR1-Mutated Breast Cancer